Regulation of aldosterone secretion in patients with chronic congestive heart failure by endothelins

American Journal of Cardiology

Volumn 85, Issue 8, 2000, Pages 973-976

  Sütsch, Gabor ^a   Bertel, Osmund ^b   Rickenbacher, Peter ^a   Clozel, Martine ^c   Yandle, Timothy G ^d   Nicholls, M Gary ^d   Kiowski, Wolfgang ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b TRIEMLI HOSPITAL   (Switzerland)

^c ACTELION PHARMACEUTICALS LTD   (Switzerland)

^d CHRISTCHURCH HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; BOSENTAN; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; PLACEBO;

ADULT; ALDOSTERONE BLOOD LEVEL; ALDOSTERONE RELEASE; ANGIOTENSIN BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ALDOSTERONE; ANGIOTENSIN II; ANTIHYPERTENSIVE AGENTS; DOUBLE-BLIND METHOD; ENDOTHELINS; HEART FAILURE, CONGESTIVE; HUMANS; MIDDLE AGED; RECEPTORS, ENDOTHELIN; SULFONAMIDES;

EID: 0342657272     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(99)00912-1     Document Type: Article

References (24)

1. Swedberg K., Eneroth P., Kjekshus J., Wilhelmsen L. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation. 82:1990;1730-1736.
2. Rouleau J.L., Packer M., Moye L., de Champlain J., Bichet D., Klein M., Rouleau J.R., Sussex B., Arnold J.M., Sestier F., et al. Prognostic value of neurohumoral activation in patients with an acute myocardial infarction effect of captopril . J Am Coll Cardiol. 24:1994;583-591.
3. Barr C.S., Lang C.C., Hanson J., Arnott M., Kennedy N., Struthers A.D. Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol. 76:1995;1259-1265.
4. MacFadyen R.J., Barr C.S., Struthers A.D. Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. Cardiovasc Res. 35:1997;30-34.
5. Wolny A., Clozel J.P., Rein J., Mory P., Vogt P., Turina M., Kiowski W., Fischli W. Functional and biochemical analysis of angiotensin II-forming pathways in the human heart. Circ Res. 80:1997;219-227.
6. Woodcock E.A., Tanner J.K., Caroccia L.M., Little P.J. Mechanisms involved in the stimulation of aldosterone production by angiotensin II, vasopressin and endothelin. Clin Exp Pharmacol Physiol. 17:1990;263-267.
7. Cavero P.G., Miller W.L., Heublein D.M., Margulies K.B., Burnett J.C.J. Endothelin in experimental congestive heart failure in the anesthetized dog. Am J Physiol. 259:1990;F312-F317.
8. Cozza E.N., Chiou S., Gomez-Sanchez C.E. Endothelin-1 potentiation of angiotensin II stimulation of aldosterone production. Am J Physiol. 262:1992;R85-R89.
9. Cozza E.N., Gomez-Sanchez C.E. Mechanisms of ET-1 potentiation of angiotensin II stimulation of aldosterone production. Am J Physiol. 265:1993;E179-E183.
10. Belloni A.S., Rossi G.P., Andreis P.G., Neri G., Albertin G., Pessina A.C., Nussdorfer G.G. Endothelin adrenocortical secretagogue effect is mediated by the B receptor in rats. Hypertension. 27:1996;1153-1159.
11. Sütsch G., Kiowski W., Yan X.W., Hunziker P., Christen S., Strobel W.M., Kim J.H., Rickenbacher P., Bertel O. Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure. Circulation. 98:1998;2262-2268.
12. Weber C., Schmitt R., Birnboeck H., Hopfgartner G., van Marle S.P., Peeters P.A., Jonkman J.H., Jones C.R. Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects. Clin Pharmacol Ther. 60:1996;124-137.
13. Lun S., Espiner E.A., Nicholls M.G., Yandle T.G. A direct radioimmunoassay for aldosterone in plasma. Clin Chem. 29:1983;268-271.
14. Rossi G.P., Albertin G., Bova S., Belloni A.S., Fallo F., Pagotto U., Trevisi L., Palu G., Pessina A.C., Nussdorfer G.G. Autocrine-paracrine role of endothelin-1 in the regulation of aldosterone synthase expression and intracellular Ca2+ in human adrenocortical carcinoma NCI-H295 cells. Endocrinology. 138:1997;4421-4426.
15. Remy-Jouet I., Cartier F., Lesouhaitier O., Kuhn J.M., Fournier A., Vaudry H., Delarue C. Mechanism of action of endothelins on adrenocortical cells. Horm Metab Res. 30:1998;341-345.
16. Pecci A., Romero D.G., Lantos C.P., Cozza E.N. Mechanisms of action of endothelial-1 in rat adrenal. Life Sci. 63:1998;1315-1328.
17. B receptor antagonists in congestive heart failure. J Am Coll Cardiol. 30:1997;1385-1392.
18. B receptor antagonist in heart failure. Cardiovasc Res. 1998;617-624.
19. Lijnen P., Staessen J., Fagard R., Amery A. Increase in plasma aldosterone during prolonged captopril treatment. Am J Cardiol. 49:1982;1561-1563.
20. B receptor subtypes. J Clin Endocrinol Metab. 82:1997;3445-3449.
21. Kiowski W., Sütsch G., Hunziker P., Müller P., Kim J., Oechslin E., Schmitt R., Jones R., Bertel O. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet. 346:1995;732-736.
22. A-receptor antagonist, in chronic heart failure. Lancet. 352:1998;201-202.
23. Pitt B., Zannad F., Remme W.J., Cody R., Castaigne A., Perez A., Palensky J., Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 341:1999;709-717.
24. Packer M, Caspi A, Charlon V, Cohel-Solal A, Kiowski W, Kostuk W, Krum H, Levine B, Massie B, McMurray J, Rizzon P, Swedberg K. Multicenter, double-blind, placebo-controlled study of long-term endothelin blockade with bosentan in chronic heart failure - results of the REACH-1 trial. Circulation 1998;98:(suppl I):I-3.